A rare pathogenic variant identified in a heart transplant recipient with hereditary transthyretin amyloidosis: a case report
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Hereditary transthyretin (ATTRv) amyloidosis is a rare and complex genetic disorder that can lead to life-threatening cardiac amyloidosis and rapid disease progression. Early diagnosis and treatment with disease-modifying drugs can improve patient outcomes; however, heart transplantation may be necessary in some patients. We present the unique case of a 65-year-old Korean woman diagnosed with ATTRv amyloidosis after experiencing progressive neurological symptoms, followed by heart failure. Despite the absence of significant symptoms of heart failure, subsequent screening revealed cardiac amyloid infiltration, which caused left ventricular hypertrophy and rapid disease progression. The patient underwent successful heart transplantation, and subsequent genetic testing revealed a pathogenic variant, NM_000371.3:c.425T>C (p.Val142Ala), which affects both the nerves and heart and has not been previously reported in Korea. Our report underscores the potential benefits of heart transplantation in managing advanced ATTRv amyloidosis and emphasizes the need for continued research on the genetic heterogeneity of the disease. Clinicians should consider ATTRv amyloidosis in the differential diagnosis of patients presenting with neurological symptoms and heart failure, particularly in those with a family history of the disease.
Abstract
Hereditary transthyretin (ATTRv) amyloidosis is a rare and complex genetic disorder that can lead to life-threatening cardiac amyloidosis and rapid disease progression. Early diagnosis and treatment with disease-modifying drugs can improve patient outcomes; however, heart transplantation may be necessary in some patients. We present the unique case of a 65-year-old Korean woman diagnosed with ATTRv amyloidosis after experiencing progressive neurological symptoms, followed by heart failure. Despite the absence of significant symptoms of heart failure, subsequent screening revealed cardiac amyloid infiltration, which caused left ventricular hypertrophy and rapid disease progression. The patient underwent successful heart transplantation, and subsequent genetic testing revealed a pathogenic variant, NM_000371.3:c.425T>C (p.Val142Ala), which affects both the nerves and heart and has not been previously reported in Korea. Our report underscores the potential benefits of heart transplantation in managing advanced ATTRv amyloidosis and emphasizes the need for continued research on the genetic heterogeneity of the disease. Clinicians should consider ATTRv amyloidosis in the differential diagnosis of patients presenting with neurological symptoms and heart failure, particularly in those with a family history of the disease.
참고문헌 (8)
- Damy T, "Transthyretin cardiac amyloidosis in continental Western Europe : an insight through the Transthyretin Amyloidosis Outcomes Survey(THAOS)", Eur Heart J, 43, pp.391~400 (2019)
- Rapezzi C, "Critical comparison of documents from scientific societies on cardiac amyloidosis : JACC State-of-the-Art Review", J Am Coll Cardiol, 79, pp.1288~1303 (2022)
- Lioncino M, "Cardiovascular involvement in transthyretin cardiac amyloidosis", Heart Fail Clin, 18, pp.73~87 (2022)
- Griffin JM, "ATTR amyloidosis : current and emerging management strategies : JACC : CardioOncology State-of-the-Art Review", JACC CardioOncol, 3, pp.488~505 (2021)
- Coelho T, "A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey(THAOS)", Amyloid, 29, pp.228~236 (2022)
- Ghoneem A, "Real-world efficacy of tafamidis in patients with transthyretin amyloidosis and heart failure", Curr Probl Cardiol, 48, pp.101667~ (2023)
- Dispenzieri A, "Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey(THAOS) : 14-year update", Orphanet J Rare Dis, 17, pp.236~ (2022)
- Chandrashekar P, "Prevalence and outcomes of p. Val142Ile TTR amyloidosis cardiomyopathy : a systematic review", Circ Genom Precis Med, 14, pp.e003356~ (2021)